寵物癌症治療市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

2024 年全球寵物癌症治療市場規模達到 4.771 億美元，預計 2025 年至 2034 年的複合年成長率為 9.7%。增強的診斷能力和尖端治療方法（包括標靶治療和免疫療法）進一步提高了獸醫癌症治療的可及性和有效性。

寵物數量老化導致癌症發生率上升，大大增加了對腫瘤學解決方案的需求。消費者行為的演變，加上獸醫學的不斷進步，凸顯了市場對寵物創新和延長壽命治療的需求日益成長。

市場按物種細分為狗、貓和其他動物。狗佔據了最大的市場佔有率，2024 年的價值為 4.02 億美元。犬腫瘤學對專科治療的需求日益成長，持續推動了對有效治療方案的需求。

根據治療方法，市場包括化療、免疫療法、標靶治療和聯合治療。化療成為主要領域，到 2024 年將佔據 62.1% 的佔有率。其在緩解方面的高成功率，尤其是對於常見的犬癌症，確保了其在獸醫腫瘤學中持續佔據重要地位。

2025 年至 2034 年期間，美國寵物癌症治療市場複合年成長率為 9.3%。這種領導地位得益於該國強大的獸醫醫療保健基礎設施、高寵物擁有率以及對晚期癌症治療的廣泛認知。對獸醫腫瘤學研究和技術的大量投資促進了創新療法的發展，包括免疫療法和標靶治療，進一步加強了美國市場。

此外，老年寵物中癌症發生率的不斷上升也持續推動了對高品質治療方案的需求。隨著人們對先進獸醫護理的認知和採用的不斷提高，寵物癌症治療市場預計將在全球範圍內實現強勁成長，北美將在塑造行業趨勢方面發揮關鍵作用。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 增強寵物的人性化
    • 寵物癌症發生率上升
    • 獸醫腫瘤診斷和治療進展
    • 提高認知和診斷能力
  • 產業陷阱與挑戰
    • 治療費用高
    • 副作用和動物耐受性
• 成長潛力分析
• 監管格局
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按物種，2021 – 2034 年

• 主要趨勢
• 狗
• 貓
• 其他物種

第 6 章：市場估計與預測：按療法，2021 – 2034 年

• 主要趨勢
• 化療
• 免疫療法
• 標靶治療
• 合併治療

第 7 章：市場估計與預測：按管理路線，2021 年至 2034 年

• 主要趨勢
• 口服
• 注射

第 8 章：市場估計與預測：按癌症類型，2021 年至 2034 年

• 主要趨勢
• 淋巴瘤
• 肥大細胞癌
• 黑色素瘤
• 乳癌和鱗狀細胞癌
• 其他癌症類型

第 9 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AB Science
• Boehringer Ingelheim International
• CureLab Oncology
• Dechra Pharmaceuticals
• Elanco Animal Health
• ELIAS Animal Health
• NovaVive
• Qbiotics
• Pfizer
• Torigen
• Vibrac
• Vivesto
• Zoetis

The Global Pet Cancer Therapeutics Market reached USD 477.1 million in 2024 and is anticipated to grow at a CAGR of 9.7% from 2025 to 2034. This growth is primarily attributed to the rising trend of pet humanization, as pet owners increasingly prioritize advanced healthcare for their animals. Enhanced diagnostic capabilities and cutting-edge treatments, including targeted therapies and immunotherapies, are further boosting the accessibility and effectiveness of veterinary cancer care.

The aging pet population has led to a higher prevalence of cancer, significantly driving the demand for oncology solutions. This evolution in consumer behavior, combined with continual advancements in veterinary medicine, underlines the growing market need for innovative and life-prolonging treatments for pets.

The market is segmented by species into dogs, cats, and other animals. Dogs held the largest market share, valued at USD 402 million in 2024. This dominance is attributed to the higher incidence of cancers such as lymphoma, osteosarcoma, and mammary tumors in dogs compared to other pets. The growing need for specialized treatments in canine oncology continues to propel the demand for effective therapeutic options.

By therapy, the market includes chemotherapy, immunotherapy, targeted therapy, and combination therapy. Chemotherapy emerged as the leading segment, generating a 62.1% share in 2024. Known for its efficacy in targeting and inhibiting the growth of cancer cells, chemotherapy remains a cornerstone of treatment for various cancers, particularly lymphoma and mast cell tumors. Its high success rates in remission, especially for common canine cancers, ensure its continued prominence in veterinary oncology.

U.S. pet cancer therapeutics market held a CAGR of 9.3% throughout 2025-2034. This leadership is driven by the country's robust veterinary healthcare infrastructure, high pet ownership rates, and widespread awareness of advanced cancer treatments. Significant investments in veterinary oncology research and technology enable the development of innovative therapies, including immunotherapy and targeted treatments, further strengthening the U.S. market.

Additionally, the increasing prevalence of cancer among aging pets continues to fuel the demand for high-quality therapeutic solutions. As awareness and adoption of advanced veterinary care rise, the pet cancer therapeutics market is expected to witness robust growth globally, with North America maintaining a pivotal role in shaping industry trends.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increased pet humanization
    • 3.2.1.2 Rising cancer incidence in pets
    • 3.2.1.3 Advancements in veterinary oncology diagnosis and treatment
    • 3.2.1.4 Growing awareness and diagnostic capabilities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Side effects and animal tolerance
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Species, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Other species

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Chemotherapy
• 6.3 Immunotherapy
• 6.4 Targeted therapy
• 6.5 Combination therapy

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injection

Chapter 8 Market Estimates and Forecast, By Cancer Type, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Lymphoma
• 8.3 Mast cell cancer
• 8.4 Melanoma
• 8.5 Mammary and squamous cell cancer
• 8.6 Other cancer types

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AB Science
• 10.2 Boehringer Ingelheim International
• 10.3 CureLab Oncology
• 10.4 Dechra Pharmaceuticals
• 10.5 Elanco Animal Health
• 10.6 ELIAS Animal Health
• 10.7 NovaVive
• 10.8 Qbiotics
• 10.9 Pfizer
• 10.10 Torigen
• 10.11 Vibrac
• 10.12 Vivesto
• 10.13 Zoetis